AACP
GYRE icon

Advantage Alpha Capital Partners’s Gyre Therapeutics GYRE Stock Holding History

Advantage Alpha Capital Partners’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-13,663
Closed -$105K – 143
2025
Q1 		$105K Buy
13,663
+4,790
+54% +$52.5K 0.03% 146
2024
Q4 		$107K Sell
8,873
-17,761
-67% -$227K 0.03% 148
2024
Q3 		$334K Buy
+26,634
New +$343K 0.08% 156

Other funds holding GYRE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Advantage Alpha Capital Partners's GYRE Position: Q2 2025 in Review

Advantage Alpha Capital Partners sold out of Gyre Therapeutics (GYRE) in Q2 2025, closing a stake of 13,663 shares — an estimated $105K sold.

Advantage Alpha Capital Partners first reported a position in GYRE in Q3 2024 and held it in 3 quarters. The position peaked at $334K in Q3 2024. 48 funds tracked by Wall St. Rank hold GYRE as of Q2 2025.

  • Advantage Alpha Capital Partners reported no remaining Gyre Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Advantage Alpha Capital Partners sold 13,663 Gyre Therapeutics shares in Q2 2025, an estimated $105K.
  • Advantage Alpha Capital Partners first reported a position in Gyre Therapeutics in Q3 2024 and held it in 3 quarters.
  • Advantage Alpha Capital Partners's Gyre Therapeutics position peaked at $334K in Q3 2024.
  • 48 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q2 2025.

Based on Advantage Alpha Capital Partners's 13F filing for Q2 2025, filed 13 Aug 2025.